Hi Reg,
absolutely right about MSB's RMAT for back pain being unique.
And its not just Athersys that's not doing so well in using its RMAT - Vericel's web site is dead cold - their autologous product's not even in their pipeline. Check it out:
The cloud has parted & it looks like we're flying alone in these skies Reg. Not a bad feeling.
Cheers
PS: I was working off the FDA's own list of granted/ refused/ withdrawns to come up with 101 as of December last - link https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/cumulative-cber-regenerative-medicine-advanced-therapy-rmat-designation-requests-received-fiscal . But some of those could have been handed back (unlikely), and some could be flying under the radar. Or their sponsors are pining for the fjords. It's tough in biotech.
Cheers
GLTA(LT)H
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-502
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.045(3.81%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $2.999M | 2.619M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 101900 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 32201 | 12 |
View Market Depth
| Last trade - 12.52pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |